These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1128 related articles for article (PubMed ID: 2065101)

  • 1. Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug Fotemustine.
    Schallreuter KU; Wood JM
    Biochim Biophys Acta; 1991 Jun; 1096(4):277-83. PubMed ID: 2065101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase.
    Schallreuter KU; Gleason FK; Wood JM
    Biochim Biophys Acta; 1990 Aug; 1054(1):14-20. PubMed ID: 2200526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas.
    Schallreuter KU; Wood JM
    Melanoma Res; 1991; 1(3):159-67. PubMed ID: 1841712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine.
    Schallreuter KU; Wood JM; Mensing H; Breitbart EW
    Cancer Chemother Pharmacol; 1991; 29(2):167-71. PubMed ID: 1760862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes.
    Boutin JA; Norbeck K; Moldeus P; Genton A; Paraire M; Bizzari JP; Lavielle G; Cudennec CA
    Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1311-6. PubMed ID: 2806354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide diphosphate reductase from human metastatic melanoma.
    Schallreuter KU; Elgren TE; Nelson LS; MacFarlan S; Yan-Sze I; Hogenkamp HP
    Melanoma Res; 1992 Dec; 2(5-6):393-400. PubMed ID: 1338000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
    Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
    J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
    Passagne I; Evrard A; Winum JY; Depeille P; Cuq P; Montero JL; Cupissol D; Vian L
    J Pharmacol Exp Ther; 2003 Nov; 307(2):816-23. PubMed ID: 12970393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium regulates thioredoxin reductase in human metastatic melanoma.
    Schallreuter KU; Wood JM
    Biochim Biophys Acta; 1989 Aug; 997(3):242-7. PubMed ID: 2765562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
    Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
    Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
    Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
    Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions.
    Brakenhoff JP; Commandeur JN; Wormhoudt LW; Groot EJ; Vermeulen NP
    Carcinogenesis; 1996 Apr; 17(4):715-24. PubMed ID: 8625482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A probable mechanism for hyperpigmentation by fotemustine.
    Schallreuter KU; Ring J
    Dermatology; 1992; 185(1):76-7. PubMed ID: 1638080
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
    Hayes MT; Bartley J; Parsons PG
    Melanoma Res; 1998 Feb; 8(1):67-75. PubMed ID: 9508380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it.
    Vermeulen NP; Commandeur JN; Groot EJ; Wormhoudt LW; Ramnatshing S; Li QJ; Brakenhoff JP
    Chem Biol Interact; 1998 Apr; 110(3):139-58. PubMed ID: 9609383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
    Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
    Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.